Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) reported late-breaking Phase 1 ELIMINATE-B data for PBGENE-HBV on November 10, 2025 showing repeat administrations (0.2, 0.4, 0.8 mg/kg) were well tolerated with no dose-limiting toxicities through a 10/31/2025 cutoff.
Across 9 patients and 22 doses, all treated participants showed measurable, dose-dependent declines in HBsAg (reductions up to 66% in Cohort 2 and a reported 64% deepening response after two doses in Cohort 3). A paired liver biopsy demonstrated ARCUS-mediated HBV DNA editing. Company expects to complete Cohort 3 dosing in Q1 2026 and to test nucleos(t)ide withdrawal if HBsAg becomes undetectable or sustainably low.
Precision BioSciences (NASDAQ: DTIL) reported Q3 2025 results and a program update. As of September 30, 2025, the company held $71.2 million in cash and expects a cash runway into the second half of 2027. Q3 results included total revenue <$0.1M, R&D of $13.4M, G&A of $7.3M, and a net loss of $21.8M (‑$1.84/share).
Clinical highlights: PBGENE-HBV advanced with dosing in Cohort 3 and a late‑breaking AASLD oral presentation on November 10, 2025; Phase 1 ELIMINATE‑B showed tolerability and one Cohort 1 patient with ~50% durable HBsAg reduction at seven months. PBGENE‑DMD IND filing is anticipated by end of 2025, with Phase 1 start in H1 2026 and initial data in H2 2026. A U.S. patent covering the HBV ARCUS nuclease expires March 2042. Imugene milestone payment of $8M received Oct 31, 2025.
Precision BioSciences (Nasdaq: DTIL) said it will publish its third quarter 2025 financial results and provide a business update on November 3, 2025. The company is a clinical-stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high-unmet-need diseases.
Investors can expect a standard quarterly results release and a corporate update on programs and operations on that date.
Precision BioSciences (Nasdaq: DTIL) was selected for a late-breaking oral presentation at AASLD The Liver Meeting® 2025 in Washington, D.C., Nov 7-11, 2025.
The presentation will report new PBGENE-HBV data from the first two cohorts of the Phase 1 ELIMINATE-B Trial, describing safety and antiviral activity. Abstract title: "PBGENE-HBV, a First-in-class Gene Editing Therapy for Chronic Hepatitis B, Demonstrates Safety and Antiviral Activity in Early Cohorts." Publication number 5017. Presentation is scheduled for Monday, November 10, 2025, 5:30PM–6:00PM EST and lists multiple clinical authors.
Precision BioSciences (NASDAQ: DTIL) reported a peer‑reviewed publication in Nucleic Acids Research describing how its engineered ARCUS nucleases drive high‑efficiency homology‑directed gene insertion and diverse edits.
Key reported results include insertion efficiencies of 60–90% in dividing cells, 20–40% in non‑dividing cells, >85% transgene insertion in T lymphocytes, and up to 40% insertion in non‑dividing primary human hepatocytes. Mechanistic data attribute these rates to ARCUS‑generated 3′ overhangs that promote homology‑mediated repair. The publication highlights ARCUS applications across insertion, single‑base edits, deletions, and large DNA replacement relevant to the company’s in‑vivo programs (examples: ECUR‑506, PBGENE‑HBV, PBGENE‑DMD).
Precision BioSciences (Nasdaq: DTIL) announced activation of its first U.S. clinical trial site for the Phase 1 ELIMINATE-B study of PBGENE-HBV at Massachusetts General Hospital in Boston, now actively recruiting chronic hepatitis B patients.
The open-label, multi-part study is evaluating safety, tolerability, dose level and dosing regimen. Precision BioSciences said Cohort 3 is underway and the company remains on track to report additional higher-dose cohort data in 2025. Trial identifier: NCT06680232.
iECURE (NYSE:DTIL) announced upcoming presentations of additional data from its ongoing OTC-HOPE clinical trial for ECUR-506, a treatment for neonatal onset ornithine transcarbamylase (OTC) deficiency. The presentations will expand on January 2025 results which showed a complete clinical response in the first treated infant.
The data will be presented at two major scientific conferences: the European Society of Gene & Cell Therapy Annual Congress (October 7-10, 2025, in Sevilla) and the American Society of Human Genetics Annual Meeting (October 14-18, 2025, in Boston). The presentations will include both oral and poster sessions focusing on this first-in-human, liver-directed, AAV-mediated gene insertion trial.
Precision BioSciences (Nasdaq: DTIL) announced a late-breaking poster presentation at the 30th Annual International Congress of the World Muscle Society in Vienna, Austria. The presentation will showcase preclinical data for PBGENE-DMD, their gene editing therapy for Duchenne Muscular Dystrophy (DMD).
The preclinical results demonstrated significant outcomes, including up to 85% dystrophin-positive cells in the gastrocnemius muscle and improved muscle function sustained through 9 months post-treatment. The therapy, designed to treat up to 60% of DMD patients with mutations between exons 45-55, showed increased dystrophin expression in multiple muscles and evidence of satellite stem cell editing.
The company remains on track to file an IND and/or CTA by the end of 2025, with initial clinical data expected in 2026.
Precision BioSciences (Nasdaq: DTIL) presented clinical data from its Phase 1 ELIMINATE-B trial of PBGENE-HBV for chronic Hepatitis B at the ICE-HBV Cure Symposium in Berlin. The company reported that PBGENE-HBV has demonstrated the first evidence of substantial HBsAg reductions through its novel therapeutic approach targeting cccDNA elimination and integrated HBV DNA inactivation.
The trial has shown that PBGENE-HBV has been well-tolerated and active across two dose levels (Cohorts 1 and 2) following multiple administrations. The company has initiated dosing in Cohort 3 and plans to provide additional data updates in 2025.
Precision BioSciences (Nasdaq: DTIL) has announced the issuance of U.S. Patent No. 12,410,418, strengthening its intellectual property portfolio for PBGENE-HBV, its lead in vivo gene editing program for chronic hepatitis B treatment. The patent, expiring in March 2042, covers composition claims for the ARCUS nuclease used in PBGENE-HBV.
The company has made progress in its Phase 1 ELIMINATE-B trial, initiating dosing in Cohort 3 during Q3 2025 while continuing safe repeat dosing in Cohort 2. The trial aims to determine optimal dosing and scheduling for achieving complete cures in chronic Hepatitis B patients. Additional patents for PBGENE-HBV were previously granted in Europe and Hong Kong earlier in 2025.